PDUFA III “Good Review Management Principles” Stress Early FDA Action
This article was originally published in The Tan Sheet
Executive Summary
FDA's "Good Review Management Principles" guidance will recognize the need to complete second- and third-round reviews of NDAs before the action goal date under the Prescription Drug User Fee Act III
You may also be interested in...
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
FDA is planning a prospective study on the root causes of multiple-cycle drug and biologic reviews as part of an effort to improve the review process, Commissioner Mark McClellan, MD/PhD, announced Jan. 31
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
FDA is planning a prospective study on the root causes of multiple-cycle drug and biologic reviews as part of an effort to improve the review process, Commissioner Mark McClellan, MD/PhD, announced Jan. 31
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
FDA is planning a prospective study on the root causes of multiple-cycle drug and biologic reviews as part of an effort to improve the review process, Commissioner Mark McClellan, MD/PhD, announced Jan. 31